Sickle Cell Disease - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Sickle Cell Disease - Pipeline Review, H2 2018’, provides an overview of the Sickle Cell Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sickle Cell Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sickle Cell Disease

- The report reviews pipeline therapeutics for Sickle Cell Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Sickle Cell Disease therapeutics and enlists all their major and minor projects

- The report assesses Sickle Cell Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Sickle Cell Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Sickle Cell Disease

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Sickle Cell Disease pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Angiocrine Bioscience Inc

Annexin Pharmaceuticals AB

ArQule Inc

Bio Products Laboratory Ltd

Bioverativ Inc

bluebird bio Inc

Bristol-Myers Squibb Co

Cell Source Inc

CRISPR Therapeutics ...

Angiocrine Bioscience Inc

Annexin Pharmaceuticals AB

ArQule Inc

Bio Products Laboratory Ltd

Bioverativ Inc

bluebird bio Inc

Bristol-Myers Squibb Co

Cell Source Inc

CRISPR Therapeutics

CSL Ltd

Editas Medicine Inc

Epizyme Inc

Errant Gene Therapeutics LLC

Fulcrum Therapeutics Inc

Gamida Cell Ltd

Genethon SA

Gilead Sciences Inc

Global Blood Therapeutics Inc

Homology Medicines, Inc.

Incyte Corp

Intellia Therapeutics Inc

Ironwood Pharmaceuticals Inc

La Jolla Pharmaceutical Company

MaxCyte Inc

Merck & Co Inc

MimeTech Srl

Morphogenesis Inc

NKT Therapeutics Inc

Novartis AG

Orphagen Pharmaceuticals Inc

Oryzon Genomics SA

Pfizer Inc

Prolong Pharmaceuticals LLC

Protagonist Therapeutics Inc

ReveraGen BioPharma Inc

Sancilio & Company Inc

Sangamo Therapeutics Inc

Syros Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Sickle Cell Disease - Overview 6

Sickle Cell Disease - Therapeutics Development 7

Sickle Cell Disease ...

Table of Contents

Table of Contents 2

Introduction 5

Sickle Cell Disease - Overview 6

Sickle Cell Disease - Therapeutics Development 7

Sickle Cell Disease - Therapeutics Assessment 17

Sickle Cell Disease - Companies Involved in Therapeutics Development 25

Sickle Cell Disease - Drug Profiles 43

Sickle Cell Disease - Dormant Projects 196

Sickle Cell Disease - Product Development Milestones 199

Appendix 211

List of Tables

List of Tables

Number of Products under Development for Sickle Cell Disease, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Tables

Number of Products under Development for Sickle Cell Disease, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Sickle Cell Disease - Pipeline by Angiocrine Bioscience Inc, H2 2018

Sickle Cell Disease - Pipeline by Annexin Pharmaceuticals AB, H2 2018

Sickle Cell Disease - Pipeline by ArQule Inc, H2 2018

Sickle Cell Disease - Pipeline by Bio Products Laboratory Ltd, H2 2018

Sickle Cell Disease - Pipeline by Bioverativ Inc, H2 2018

Sickle Cell Disease - Pipeline by bluebird bio Inc, H2 2018

Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Co, H2 2018

Sickle Cell Disease - Pipeline by Cell Source Inc, H2 2018

Sickle Cell Disease - Pipeline by CRISPR Therapeutics, H2 2018

Sickle Cell Disease - Pipeline by CSL Ltd, H2 2018

Sickle Cell Disease - Pipeline by Editas Medicine Inc, H2 2018

Sickle Cell Disease - Pipeline by Epizyme Inc, H2 2018

Sickle Cell Disease - Pipeline by Errant Gene Therapeutics LLC, H2 2018

Sickle Cell Disease - Pipeline by Fulcrum Therapeutics Inc, H2 2018

Sickle Cell Disease - Pipeline by Gamida Cell Ltd, H2 2018

Sickle Cell Disease - Pipeline by Genethon SA, H2 2018

Sickle Cell Disease - Pipeline by Gilead Sciences Inc, H2 2018

Sickle Cell Disease - Pipeline by Global Blood Therapeutics Inc, H2 2018

Sickle Cell Disease - Pipeline by Homology Medicines, Inc., H2 2018

Sickle Cell Disease - Pipeline by Incyte Corp, H2 2018

Sickle Cell Disease - Pipeline by Intellia Therapeutics Inc, H2 2018

Sickle Cell Disease - Pipeline by Ironwood Pharmaceuticals Inc, H2 2018

Sickle Cell Disease - Pipeline by La Jolla Pharmaceutical Company, H2 2018

Sickle Cell Disease - Pipeline by MaxCyte Inc, H2 2018

Sickle Cell Disease - Pipeline by Merck & Co Inc, H2 2018

Sickle Cell Disease - Pipeline by MimeTech Srl, H2 2018

Sickle Cell Disease - Pipeline by Morphogenesis Inc, H2 2018

Sickle Cell Disease - Pipeline by NKT Therapeutics Inc, H2 2018

Sickle Cell Disease - Pipeline by Novartis AG, H2 2018

Sickle Cell Disease - Pipeline by Orphagen Pharmaceuticals Inc, H2 2018

Sickle Cell Disease - Pipeline by Oryzon Genomics SA, H2 2018

Sickle Cell Disease - Pipeline by Pfizer Inc, H2 2018

Sickle Cell Disease - Pipeline by Prolong Pharmaceuticals LLC, H2 2018

Sickle Cell Disease - Pipeline by Protagonist Therapeutics Inc, H2 2018

Sickle Cell Disease - Pipeline by ReveraGen BioPharma Inc, H2 2018

Sickle Cell Disease - Pipeline by Sancilio & Company Inc, H2 2018

Sickle Cell Disease - Pipeline by Sangamo Therapeutics Inc, H2 2018

Sickle Cell Disease - Pipeline by Syros Pharmaceuticals Inc, H2 2018

Sickle Cell Disease - Dormant Projects, H2 2018

Sickle Cell Disease - Dormant Projects, H2 2018 (Contd..1), H2 2018

Sickle Cell Disease - Dormant Projects, H2 2018 (Contd..2), H2 2018

List of Figures

List of Figures

Number of Products under Development for Sickle Cell Disease, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Figures

Number of Products under Development for Sickle Cell Disease, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports